Research Output per year
Fingerprint Dive into the research topics where Silvio Garattini is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 4 Similar Profiles
Fenfluramine
Medicine & Life Sciences
Pharmaceutical Preparations
Medicine & Life Sciences
Brain
Medicine & Life Sciences
Serotonin
Medicine & Life Sciences
Rats
Chemical Compounds
Norfenfluramine
Medicine & Life Sciences
Appetite Depressants
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 1952 2019
Looking for safety but overlooking efficacy: Non-inferiority trials of anti-diabetics
Bertele', V., Banzi, R., Gerardi, C. & Garattini, S., Sep 2019, In : European Journal of Internal Medicine. 67, p. e9-e10Research output: Contribution to journal › Article
A disease looking for innovative drugs: The case of pulmonary arterial hypertension
Joppi, R., Gerardi, C., Bertele', V. & Garattini, S., Sep 2018, In : European Journal of Internal Medicine. 55, p. 47-51 5 p.Research output: Contribution to journal › Article
Pulmonary Hypertension
Pharmaceutical Preparations
Meta-Analysis
Marketing
Therapeutics
9
Citations
(Scopus)
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues
Pusceddu, S., Vernieri, C., Di Maio, M., Marconcini, R., Spada, F., Massironi, S., Ibrahim, T., Brizzi, M. P., Campana, D., Faggiano, A., Giuffrida, D., Rinzivillo, M., Cingarlini, S., Aroldi, F., Antonuzzo, L., Berardi, R., Catena, L., De Divitiis, C., Ermacora, P., Perfetti, V. & 30 others, , Aug 1 2018, In : Gastroenterology. 155, 2, p. 479-489.e7Research output: Contribution to journal › Article
Neuroendocrine Tumors
Metformin
Somatostatin
Disease-Free Survival
Everolimus
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues
Pusceddu, S., Vernieri, C., Di Maio, M., Marconcini, R., Spada, F., Massironi, S., Ibrahim, T., Brizzi, M. P., Campana, D., Faggiano, A., Giuffrida, D., Rinzivillo, M., Cingarlini, S., Aroldi, F., Antonuzzo, L., Berardi, R., Catena, L., De Divitiis, C., Ermacora, P., Perfetti, V. & 32 others, , 2018, In : Gastroenterology. 155, 2, p. 479Research output: Contribution to journal › Article
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues
Pusceddu, S., Vernieri, C., Di Maio, M., Marconcini, R., Spada, F., Massironi, S., Ibrahim, T., Brizzi, M. P., Campana, D., Faggiano, A., Giuffrida, D., Rinzivillo, M., Cingarlini, S., Aroldi, F., Antonuzzo, L., Berardi, R., Catena, L., De Divitiis, C., Ermacora, P., Perfetti, V. & 32 others, , Aug 2018, In : Gastroenterology. 155, 2, p. 479-489.e7Research output: Contribution to journal › Article
Neuroendocrine Tumors
Metformin
Somatostatin
Disease-Free Survival
Everolimus